BioCentury
ARTICLE | Clinical News

CDX-1307: Phase II started

May 24, 2010 7:00 AM UTC

Celldex began a U.S. Phase II trial in about 60 patients with newly diagnosed hCG-beta expressing muscle-invasive bladder cancer. Patients will receive neoadjuvant therapy with CDX-1307 plus cisplatin...